The ISNS/Wallac Robert Guthrie Award
The Robert Guthrie Award shall be given annually to honour an ISNS member who has made an outstanding contribution to newborn or other population based screening which is recognised as such worldwide. The award shall include a cash prize of US$ 4000 donated by Wallac Oy (Finland) .
Nomination for the Robert Guthrie Award may be made by any active ISNS member and must be seconded by at least two other active members of the ISNS. The nomination must be accompanied by a statement of 100-200 words which describes the nature of the contribution. More details can be seen on the Society's website, and can be obtained from the Secretary-Treasurer.
Meetings
THE 5TH ISNS SYMPOSIUM GENOA, ITALY Dr Robert Cerone and his team have set the date for the 5th international neonatal screening symposium to be June 2002 in Genoa, Italy. Further details are being worked out and will be announced as they become available. THE 6TH ISNS SYMPOSIUM After successful ISNS meetings in Leura (Australia; 1991) , Lille (France, 1993) , Boston (USA, 1996) , Stockholm (Sweden, 1999) and the forthcoming meeting in Genoa (Italy, 2002) , the ISNS will have to consider the meeting to be held in 2005. In view of the locations of the previous meetings, it may be that the 6th ISNS Symposium should not be held in Europe. Bids to host such a meeting, accompanied by details concerning organisation, sponsoring, and a preliminary programme, should be sent to the Secretary-Treasurer by the end of May, 2001.
Past meetings
During the year 2000, scientific meetings have been held all around the world in which neonatal screening was addressed in some form. Examples were the Benelux meeting in Brugge in March, the German meeting in Weilburg in June, the Nordic meeting in Copenhagen in September, the SSIEM meeting in Cambridge in September, and the Sino-Japanese meeting in Shanghai in November.
Common denominators for all these meetings were the introduction of the screening for congenital adrenal hyperplasia and further experiments with screening for cystic fibrosis, but above all, extensive discussions on the pros and cons of tandem mass spectrometry screening. On the ISNS page of the previous issue of this Journal, Dr Brad Therrell reported on the points of view in the United States, whereas Dr Bridget Wilcken formulated the ISNS approach to new screening programmes in general. The problems of evaluating the benefits of an existing or planned newborn screening programme are immense, largely because of considerations of power. Few disorders have a birth prevalence suYcient to make a randomised controlled trial possible. The value of new screening programmes can only be appreciated in the local context, and the results of pilot programmes elsewhere cannot always be taken for granted in the local situation. Nevertheless, we need to rely on evidence from colleagues all over the world before a balanced decision can be reached. 
Forthcoming meetings

Membership certificates and seals
Until 2000 the ISNS Secretariat issued a membership certificate to new members and annually a seal to current members. However, due to continued technical diYculties in obtaining the seals, the Executive Board decided earlier this year to discontinue both the certificates and the seals. If a member needs written proof of his/her ISNS membership, the Secretariat is willing to send a letter of confirmation. The UK Health Technology Assessment (HTA) Programme web site contains executive summaries and full text versions (in Adobe Acrobat format) of published monographs: (http://www.ncchta.org).
Printed copies of monographs may be ordered either from the web site publications page or by faxing to: 02380 595 639. Copies are free of charge for staV working in the public sector in the UK. Orders for forthcoming monographs will be held and fulfilled on publication.
If you have access to a fax machine you can obtain faxed copies of executive summaries of monographs (from volume 4 onwards only) by dialling 02380 595 596 and following the voice prompts. Other documents such as information sheets about the HTA programme are also available by faxback. Please do not send faxes to this number. 
LETTER TO THE EDITOR
Revised distribution parameters for serum markers for trisomy 18
We recently showed that the assay precision of maternal serum fetoprotein ( FP) has improved over the past decade with estimates of the standard deviation about 30% lower than those previously published and that this is expected, to a small extent, to have improved the performance of antenatal screening for open neural tube defects and Down's syndrome. 1 As a result of the improvement in assay precision, there will also be a reduction in the standard deviation of FP in trisomy 18 pregnancies. We adopted the same methodology to revise the parameters used to estimate the risk of having an aVected pregnancy.
In 1995 we published statistical parameters (means, standard deviations, and correlation coeYcients) which allowed pregnancies with an increased risk of trisomy 18 to be identified as part of a screening programme for Down's syndrome, using maternal serum markers in the second trimester of pregnancy; the markers were serum FP, unconjugated oestriol (uE 3 ), total human chorionic gonadotrophin (hCG) and its subunit free -hCG. 2 The revised standard deviation for FP in trisomy 18 pregnancies is 0.1980 (previously 0.2239), and the revised correlation coeYcients between FP and uE 3 , total hCG, and free -hCG are 0.2466, 0.0612, and 0.1644 respectively. The false positive rate for a 60% detection rate using the double test (maternal age with FP and free -hCG) is 3.17% using the revised parameters compared with 3.46% using the previously published ones (or 2.33% and 2.60% respectively using total hCG instead of free -hCG); with the triple test (double test plus uE 3 ) the estimates are 0.25% and 0.26% respectively (or 0.20% and 0.22% respectively using total hCG instead of free -hCG). As previously published, 1 in unaVect-ed pregnancies the revised standard deviation is 0.1688 (previously 0.1986) and the correlation coeYcients between FP and uE 3 , total hCG and free -hCG are 0.2459, 0.0859, and 0.0843 respectively. Although the changes are small, they allow a common set of parameters to be used in screening for Down's syndrome and the antenatal identification of trisomy 18. 
